

July 28, 2008

Corporate Name: Alfresa Holdings Corporation  
Representative: Arata Watanabe, Representative Director & President  
Code: 2784 (1<sup>st</sup> Section, Tokyo Stock Exchange;  
1<sup>st</sup> Section, Osaka Securities Exchange)  
Contact: Shunichi Miyake, Vice President & Executive Officer,  
Financial Planning, Public & Investor Relations,  
General Manager of Financial Planning Department  
(E-mail: ir@alfresa.com)

Corporate Name: Nobelpharma Co., Ltd.  
Representative: Jin Shiomura, Representative Director & CEO  
(Unlisted)  
Contact: Tsutomu Sugaya, Executive Director,  
Head of Corporate Planning & Business Development

**Notice of Conclusion of Partnership Agreement Concerning  
Marketing and Development between Alfresa Pharma Corporation and  
Nobelpharma Co., Ltd.**

Alfresa Pharma Corporation (headquarters: Osaka, President & CEO: Tetsuo Kure, hereinafter “Alfresa Pharma”), a subsidiary of Alfresa Holdings Corporation engaged in the manufacturing of pharmaceuticals, etc., concluded with Nobelpharma Co., Ltd. (headquarters: Chuo-ku, Tokyo, Representative Director & CEO: Jin Shiomura, hereinafter “Nobelpharma”) a basic agreement concerning the right to have priority in negotiating for a marketing partnership for ethical pharmaceuticals that Nobelpharma is to obtain approval for in the future to manufacture and market in Japan and which are not subject to licensing restrictions, and concerning cooperation in developing partnership products. At present the two companies are discussing a marketing partnership for products in the field of the central nervous system into which Alfresa Pharma is channeling its energies.

As Nobelpharma does not have its own marketing framework, it plans to continue expanding the development pipeline in the future through pharmaceuticals for which there are unmet needs. Meanwhile, Alfresa Pharma is aiming at expanding in-house development as well as partnerships, including marketing alliance, with a view to further securing the pipeline. The expansion of the alliance this time was realized based on the agreement between both companies that this move could mutually strengthen complementary relations.

With respect to NOBELZIN® capsules (generic name: zinc acetate dihydrate) for the treatment of Wilson’s disease of which Nobelpharma has obtained approval for the

manufacturing and marketing, both companies have already concluded an agreement under which Alfresa Pharma can exclusively market this product in Japan. By expanding the partnership this time, both companies intend to further contribute to the improvement of medical treatment in Japan based on the mutual trust they have developed through the marketing partnership for NOBELZIN®.

### **Profile of Each Company**

#### Alfresa Holdings Corporation

Establishment: September 2003  
Address of head office: 1-1-3 Otemachi, Chiyoda-ku, Tokyo  
Representative: Arata Watanabe, Representative Director & President  
Net sales: 1,769,454 million yen (fiscal year ended March 2008, consolidated basis)  
Number of employees: 10,517 (fiscal year ended March 2008, consolidated basis)  
Main business: Management of subsidiaries engaged in wholesaling, manufacturing, marketing and export/import of pharmaceuticals, diagnostic reagents, and medical devices/equipment, etc.

#### Alfresa Pharma Corporation

Establishment: December 1939  
Address of head office: 2-2-9 Kokumachi, Chuo-ku, Osaka  
Representative: Tetsuo Kure, President & CEO  
Net sales: 24,704 million yen (fiscal year ended March 2008)  
Number of employees: 636 (fiscal year ended March 2008)  
Main business: Manufacturing, import/export and marketing of pharmaceuticals, diagnostic reagents, medical devices, and materials for pharmaceuticals, etc.

#### Nobelpharma Co., Ltd.

Establishment: June 2003  
Address of head office: 12-10 Nihonbashi-kobunacho, Chuo-ku, Tokyo  
Representative: Jin Shiomura, Representative Director & CEO  
Net sales: 230 million yen (fiscal year ended December 2007)  
Number of employees: 52 (end of June 2008)  
Main business: Development, manufacturing, import/export and marketing of pharmaceuticals and medical devices, etc.